abstract |
The present invention provides a novel macrocyclic compound exhibiting agonistic or antagonistic activity against a motilin receptor, a serotonin receptor and a prostaglandin F2A receptor. A macrocyclic compound represented by formula (I) in which building blocks A, B and C are incorporated. [Efficacy] It is effective for the treatment of hypokinetic disorders of the gastrointestinal tract, CNS related diseases and ocular hypertension. [Selection figure] None |